How much profit has Virbac made this year?
Virbac has made 142.42 M EUR this year.
Virbac Net Income 2024
Virbac Net Income
142.42 M EUR
Ticker
VIRP.PA
ISIN
FR0000031577
WKN
874929
In 2024, Virbac's profit amounted to 142.42 M EUR, a 17.41% increase from the 121.3 M EUR profit recorded in the previous year.
The Virbac Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2028e | 222.72 |
| 2027e | 203.4 |
| 2026e | 181.38 |
| 2025e | 160.06 |
| 2024e | 142.42 |
| 2023 | 121.3 |
| 2022 | 121.97 |
| 2021 | 113.16 |
| 2020 | 136.04 |
| 2019 | 51.55 |
| 2018 | 20.1 |
| 2017 | -2.58 |
| 2016 | 34.65 |
| 2015 | 9.41 |
| 2014 | 63.6 |
| 2013 | 60.52 |
| 2012 | 66.63 |
| 2011 | 57.52 |
| 2010 | 63.41 |
| 2009 | 38.82 |
| 2008 | 35.41 |
| 2007 | 31.04 |
| 2006 | 24.91 |
| 2005 | 19.8 |
| 2004 | 16.73 |
Virbac Revenue, EBIT, Net Income FR0000031577 · 874929
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Virbac, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Virbac from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Virbac’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Virbac. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Virbac’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Virbac’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Virbac’s growth potential.
Virbac Revenue, Profit, and EBIT History
| Date | Virbac Revenue | Virbac EBIT | Virbac Net Income |
|---|---|---|---|
| 2028e | 1.66 B undefined | 317.35 M undefined | 222.72 M undefined |
| 2027e | 1.6 B undefined | 293.76 M undefined | 203.4 M undefined |
| 2026e | 1.57 B undefined | 259.34 M undefined | 181.38 M undefined |
| 2025e | 1.51 B undefined | 233.61 M undefined | 160.06 M undefined |
| 2024e | 1.4 B undefined | 209.39 M undefined | 142.42 M undefined |
| 2023 | 1.25 B undefined | 185.21 M undefined | 121.3 M undefined |
| 2022 | 1.22 B undefined | 183.68 M undefined | 121.97 M undefined |
| 2021 | 1.06 B undefined | 169.24 M undefined | 113.16 M undefined |
| 2020 | 934.2 M undefined | 121.78 M undefined | 136.04 M undefined |
| 2019 | 938.34 M undefined | 105.01 M undefined | 51.55 M undefined |
| 2018 | 868.93 M undefined | 75.03 M undefined | 20.1 M undefined |
| 2017 | 861.88 M undefined | 58.58 M undefined | -2.58 M undefined |
| 2016 | 871.83 M undefined | 68.94 M undefined | 34.65 M undefined |
| 2015 | 852.62 M undefined | 35.08 M undefined | 9.41 M undefined |
| 2014 | 773.12 M undefined | 109.6 M undefined | 63.6 M undefined |
| 2013 | 736.08 M undefined | 104.43 M undefined | 60.52 M undefined |
| 2012 | 695.16 M undefined | 97.88 M undefined | 66.63 M undefined |
| 2011 | 623.06 M undefined | 86.33 M undefined | 57.52 M undefined |
| 2010 | 572.83 M undefined | 88.56 M undefined | 63.41 M undefined |
| 2009 | 467.42 M undefined | 58.43 M undefined | 38.82 M undefined |
| 2008 | 443.36 M undefined | 54.07 M undefined | 35.41 M undefined |
| 2007 | 438.55 M undefined | 51.88 M undefined | 31.04 M undefined |
| 2006 | 401.64 M undefined | 42.1 M undefined | 24.91 M undefined |
| 2005 | 372.4 M undefined | 32.09 M undefined | 19.8 M undefined |
| 2004 | 351.4 M undefined | 28.25 M undefined | 16.73 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 351.4 M EUR | 28.25 M EUR | 16.73 M EUR |
| 2005 | 372.4 M EUR | 32.09 M EUR | 19.8 M EUR |
| 2006 | 401.64 M EUR | 42.1 M EUR | 24.91 M EUR |
| 2007 | 438.55 M EUR | 51.88 M EUR | 31.04 M EUR |
| 2008 | 443.36 M EUR | 54.07 M EUR | 35.41 M EUR |
| 2009 | 467.42 M EUR | 58.43 M EUR | 38.82 M EUR |
| 2010 | 572.83 M EUR | 88.56 M EUR | 63.41 M EUR |
| 2011 | 623.06 M EUR | 86.33 M EUR | 57.52 M EUR |
| 2012 | 695.16 M EUR | 97.88 M EUR | 66.63 M EUR |
| 2013 | 736.08 M EUR | 104.43 M EUR | 60.52 M EUR |
| 2014 | 773.12 M EUR | 109.6 M EUR | 63.6 M EUR |
| 2015 | 852.62 M EUR | 35.08 M EUR | 9.41 M EUR |
| 2016 | 871.83 M EUR | 68.94 M EUR | 34.65 M EUR |
| 2017 | 861.88 M EUR | 58.58 M EUR | -2.58 M EUR |
| 2018 | 868.93 M EUR | 75.03 M EUR | 20.1 M EUR |
| 2019 | 938.34 M EUR | 105.01 M EUR | 51.55 M EUR |
| 2020 | 934.2 M EUR | 121.78 M EUR | 136.04 M EUR |
| 2021 | 1.06 B EUR | 169.24 M EUR | 113.16 M EUR |
| 2022 | 1.22 B EUR | 183.68 M EUR | 121.97 M EUR |
| 2023 | 1.25 B EUR | 185.21 M EUR | 121.3 M EUR |
| 2024e | 1.4 B EUR | 209.39 M EUR | 142.42 M EUR |
| 2025e | 1.51 B EUR | 233.61 M EUR | 160.06 M EUR |
| 2026e | 1.57 B EUR | 259.34 M EUR | 181.38 M EUR |
| 2027e | 1.6 B EUR | 293.76 M EUR | 203.4 M EUR |
| 2028e | 1.66 B EUR | 317.35 M EUR | 222.72 M EUR |
Virbac stock margins FR0000031577 · 874929
The Virbac margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Virbac. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Virbac.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Virbac's sales revenue. A higher gross margin percentage indicates that the Virbac retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Virbac's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Virbac's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Virbac's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Virbac. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Virbac's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Virbac Margin History
| Virbac Gross margin | Virbac Profit margin | Virbac EBIT margin | Virbac Profit margin |
|---|---|---|---|
| 2028e | 64.93 % | 19.06 % | 13.38 % |
| 2027e | 64.93 % | 18.37 % | 12.72 % |
| 2026e | 64.93 % | 16.49 % | 11.53 % |
| 2025e | 64.93 % | 15.51 % | 10.63 % |
| 2024e | 64.93 % | 14.9 % | 10.14 % |
| 2023 | 64.93 % | 14.85 % | 9.73 % |
| 2022 | 45.59 % | 15.1 % | 10.03 % |
| 2021 | 47.5 % | 15.91 % | 10.64 % |
| 2020 | 48.66 % | 13.04 % | 14.56 % |
| 2019 | 49.22 % | 11.19 % | 5.49 % |
| 2018 | 48.1 % | 8.63 % | 2.31 % |
| 2017 | 43.56 % | 6.8 % | -0.3 % |
| 2016 | 44.24 % | 7.91 % | 3.97 % |
| 2015 | 40.16 % | 4.11 % | 1.1 % |
| 2014 | 46.32 % | 14.18 % | 8.23 % |
| 2013 | 46.14 % | 14.19 % | 8.22 % |
| 2012 | 45.64 % | 14.08 % | 9.58 % |
| 2011 | 45.3 % | 13.86 % | 9.23 % |
| 2010 | 44.05 % | 15.46 % | 11.07 % |
| 2009 | 44.09 % | 12.5 % | 8.3 % |
| 2008 | 43.36 % | 12.2 % | 7.99 % |
| 2007 | 42.36 % | 11.83 % | 7.08 % |
| 2006 | 43.47 % | 10.48 % | 6.2 % |
| 2005 | 43.71 % | 8.62 % | 5.32 % |
| 2004 | 43.08 % | 8.04 % | 4.76 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 43.08 % | 8.04 % | 4.76 % |
| 2005 | 43.71 % | 8.62 % | 5.32 % |
| 2006 | 43.47 % | 10.48 % | 6.2 % |
| 2007 | 42.36 % | 11.83 % | 7.08 % |
| 2008 | 43.36 % | 12.2 % | 7.99 % |
| 2009 | 44.09 % | 12.5 % | 8.3 % |
| 2010 | 44.05 % | 15.46 % | 11.07 % |
| 2011 | 45.3 % | 13.86 % | 9.23 % |
| 2012 | 45.64 % | 14.08 % | 9.58 % |
| 2013 | 46.14 % | 14.19 % | 8.22 % |
| 2014 | 46.32 % | 14.18 % | 8.23 % |
| 2015 | 40.16 % | 4.11 % | 1.1 % |
| 2016 | 44.24 % | 7.91 % | 3.97 % |
| 2017 | 43.56 % | 6.8 % | -0.3 % |
| 2018 | 48.1 % | 8.63 % | 2.31 % |
| 2019 | 49.22 % | 11.19 % | 5.49 % |
| 2020 | 48.66 % | 13.04 % | 14.56 % |
| 2021 | 47.5 % | 15.91 % | 10.64 % |
| 2022 | 45.59 % | 15.1 % | 10.03 % |
| 2023 | 64.93 % | 14.85 % | 9.73 % |
| 2024e | 64.93 % | 14.9 % | 10.14 % |
| 2025e | 64.93 % | 15.51 % | 10.63 % |
| 2026e | 64.93 % | 16.49 % | 11.53 % |
| 2027e | 64.93 % | 18.37 % | 12.72 % |
| 2028e | 64.93 % | 19.06 % | 13.38 % |
Virbac Aktienanalyse
What does Virbac do?
Virbac SA is a French company specializing in animal medicines and care products. The company was founded in 1968 by Pierre Richard Dick, who studied veterinary medicine at the École nationale vétérinaire d'Alfort and gained experience as a veterinarian. Since its founding, Virbac SA has been headquartered near Carros, France and operates worldwide. The business model of Virbac SA is to offer a wide range of products to veterinarians and pet owners, aiming to ensure optimal health, care, and quality of life for their pets. This includes everything from vaccines, diagnostics, and medications to grooming products that veterinarians and pet owners need to ensure optimal pet healthcare. Virbac SA has five main business areas, namely livestock, pets, horses, hygiene products, and specialties. The livestock sector includes products such as feed additives and antiparasitics tailored to the specific needs of cattle, pigs, poultry, and fish. In the pets sector, Virbac SA offers products specifically tailored to dogs, cats, birds, and other pets. This includes both disease prevention and treatment products. In the horse sector, the company offers products for the maintenance, care, and health of horses. Another division of Virbac SA is hygiene products. The company offers a wide portfolio of products and solutions that support both veterinarians and pet owners in ensuring the health and care of animals. This ranges from infection control products to animal-specific shampoos and grooming items. The specialties sector, on the other hand, includes specialized products such as targeted diagnostics, therapeutics, and dietary supplements. The constant focus on research and development also leads to innovative product launches that consistently meet the highest quality standards. An example of this is the scientifically developed dental hygiene product line that improves both the oral health and breath quality of dogs and cats. For this, Virbac SA also receives awards from the Veterinary Center for Clinical Medicine in Munich. Through a systematic international expansion strategy, Virbac SA is now present in more than 100 countries. The company employs over 4,800 people worldwide and achieved a turnover of 954 million euros in 2019. Overall, Virbac SA stands for consistently high product quality and a strong customer orientation. With a combination of expertise and extensive scientific research and development, particularly in the field of animal health and care, the company is an important player in the global animal medicine manufacturing market. Virbac ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Virbac's Profit Margins
The profit margins of Virbac represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Virbac's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Virbac's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Virbac's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Virbac’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Virbac Stock
How has the profit developed compared to last year?
The profit has increased by 17.41% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Virbac publish its earnings?
Virbac publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Virbac?
The profits of Virbac are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Virbac?
You can learn more about the earnings of Virbac by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Virbac pay?
Over the past 12 months, Virbac paid a dividend of 1.32 EUR . This corresponds to a dividend yield of about 0.4 %. For the coming 12 months, Virbac is expected to pay a dividend of 1.5 EUR.
What is the dividend yield of Virbac?
The current dividend yield of Virbac is 0.4 %.
When does Virbac pay dividends?
Virbac pays a quarterly dividend. This is distributed in the months of July, July, July, July.
How secure is the dividend of Virbac?
Virbac paid dividends every year for the past 8 years.
What is the dividend of Virbac?
For the upcoming 12 months, dividends amounting to 1.5 EUR are expected. This corresponds to a dividend yield of 0.45 %.
In which sector is Virbac located?
Virbac is assigned to the 'Health' sector.
Wann musste ich die Aktien von Virbac kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Virbac from 6/27/2024 amounting to 1.32 EUR, you needed to have the stock in your portfolio before the ex-date on 6/25/2024.
When did Virbac pay the last dividend?
The last dividend was paid out on 6/27/2024.
What was the dividend of Virbac in the year 2023?
In the year 2023, Virbac distributed 1.25 EUR as dividends.
In which currency does Virbac pay out the dividend?
The dividends of Virbac are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Virbac stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Virbac
Our stock analysis for Virbac Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Virbac Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
